Coherus Biosciences price target raised to $22 from $18 at Maxim. Maxim analyst Jason McCarthy raised his price target on Coherus Biosciences to $22 from $18 after the company announced that the FDA has accepted for review the recently re-submitted BLA for CHS-1701, a biosimilar version of Neulasta. The BSUFA date for a decision is November 3, he noted. The analyst keeps his Buy rating on Coherus Biosciences shares
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.